One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Flashback Foreword: Pazopanib in Renal Cell Carcinoma and Overall Survival With Sunitinib Versus Interferon-[alpha] in Metastatic Renal Cell Carcinoma.
Carducci, Michael A. MD 1,2,,
doi : 10.1200/JCO.23.00153
Volume 41(11) pgs. 1955-2121,e21-e41 April 10, 2023
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial.
Sternberg, Cora N.; Davis, Ian D.; Mardiak, Jozef; Szczylik, Cezary; Lee, Eunsik; Wagstaff, John; Barrios, Carlos H.; Salman, Pamela; Gladkov, Oleg A.; Kavina, Alexander; Zarba, Juan J.; Chen, Mei; McCann, Lauren; Pandite, Lini; Roychowdhury, Debasish F.; Hawkins, Robert E.
doi : 10.1200/JCO.22.02622
Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit.
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma.
Motzer, Robert J.; Hutson, Thomas E.; Tomczak, Piotr; Michaelson, M. Dror; Bukowski, Ronald M.; Oudard, Stephane; Negrier, Sylvie; Szczylik, Cezary; Pili, Roberto; Bjarnason, Georg A.; Garcia-del-Muro, Xavier; Sosman, Jeffrey A.; Solska, Ewa; Wilding, George; Thompson, John A.; Kim, Sindy T.; Chen, Isan; Huang, Xin; Figlin, Robert A.
doi : 10.1200/JCO.22.02623
A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-[alpha]) in progression-free survival (primary end point) as first-line treatment for metastatic renal cell carcinoma (RCC).
Adjuvant Gemcitabine and Nab-Paclitaxel Misses the Target in Pancreas Adenocarcinoma: Or Did an Effective Therapy Fall to the Definition of Recurrence?.
Manji, Gulam A. MD, PhD 1,2,3,,
doi : 10.1200/JCO.23.00039
The National Clinical Trials Network: A Valuable and Undervalued Resource.
Burris, Howard A. III MD 1,,
doi : 10.1200/JCO.22.02628
Long-Term Outcomes in Resected IDH-Mutant Subtypes of Diffuse Low-Grade Glioma.
Diez Valle, Ricardo MD, PhD 1,
doi : 10.1200/JCO.22.02428
Yes, We Can, But Should We? Ethical Considerations in Reporting Germline Findings From Paired Tumor-Normal Genomic Testing in Patients With Advanced Cancer.
Hunter, Cynthia L. MS, CGC 1,2,; Helft, Paul R. MD 3
doi : 10.1200/JCO.22.00796
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score >= 1% in the KEYNOTE-042 Study.
de Castro, Gilberto Jr MD, PhD 1,,; Kudaba, Iveta MD 2; Wu, Yi-Long MD 3,; Lopes, Gilberto MD 4,; Kowalski, Dariusz M. MD, PhD 5,; Turna, Hande Z. MD 6; Caglevic, Christian MD 7,; Zhang, Li MD 8; Karaszewska, Boguslawa MD 9; Laktionov, Konstantin K. MD 10; Srimuninnimit, Vichien MD 11; Bondarenko, Igor MD 12; Kubota, Kaoru MD, PhD 13,; Mukherjee, Rinee PhD 14; Lin, Jianxin MS 14,; Souza, Fabricio MD 14,; Mok, Tony S.K. MD 15,; Cho, Byoung Chul MD, PhD 16,
doi : 10.1200/JCO.21.02885
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
Garassino, Marina C. MD 1,2,,; Gadgeel, Shirish MD 3,; Speranza, Giovanna MD, MSc 4,; Felip, Enriqueta MD, PhD 5,; Esteban, Emilio MD 6,; Domine, Manuel MD 7,; Hochmair, Maximilian J. MD 8,; Powell, Steven F. MD 9,; Bischoff, Helge G. MD 10; Peled, Nir MD 11; Grossi, Francesco MD 12,; Jennens, Ross R. MBBS 13; Reck, Martin MD, PhD 14,; Hui, Rina MBBS, PhD 15,; Garon, Edward B. MD 16,; Kurata, Takayasu MD 17,; Gray, Jhanelle E. MD 18,; Schwarzenberger, Paul MD 19,; Jensen, Erin MS 19,; Pietanza, M. Catherine MD 19,; Rodriguez-Abreu, Delvys MD, PhD 20,
doi : 10.1200/JCO.22.01989
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically on the based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.
Novello, Silvia MD, PhD 1,,; Kowalski, Dariusz M. MD, PhD 2,; Luft, Alexander MD, PhD 3; Gumus, Mahmut MD 4,; Vicente, David MD 5,; Mazieres, Julien MD, PhD 6,; Rodriguez-Cid, Jeronimo MD 7,; Tafreshi, Ali MD 8; Cheng, Ying MD 9; Lee, Ki Hyeong MD, PhD 10,; Golf, Alexander MD 11; Sugawara, Shunichi MD, PhD 12,; Robinson, Andrew G. MD 13,; Halmos, Balazs MD 14,; Jensen, Erin MS 15,; Schwarzenberger, Paul MD 16,; Pietanza, M. Catherine MD 16,; Paz-Ares, Luis MD, PhD 17,
doi : 10.1200/JCO.22.01990
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.
Tempero, Margaret A. MD 1,,; Pelzer, Uwe MD 2; O'Reilly, Eileen M. MD 3,; Winter, Jordan MD 4; Oh, Do-Youn MD 5,6,; Li, Chung-Pin MD, PhD 7,8,9; Tortora, Giampaolo MD 10,11,; Chang, Heung-Moon MD 12,; Lopez, Charles D. MD, PhD 13,; Bekaii-Saab, Tanios MD 14,; Ko, Andrew H. MD 1,; Santoro, Armando MD 15,16,; Park, Joon Oh MD, PhD 17,; Noel, Marcus S. MD 18,;
doi : 10.1200/JCO.22.01134
This randomized, open-label trial compared the efficacy and safety of adjuvant nab-paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic ductal adenocarcinoma (ClinicalTrials.gov identifier: NCT01964430).
Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies.
Unger, Joseph M. PhD, MS 1,; LeBlanc, Michael PhD 1,; George, Suzanne MD 2,; Wolmark, Norman MD 3,4,; Curran, Walter J. Jr MD 5,; O'Dwyer, Peter J. MD 6,; Schnall, Mitchell D. MD, PhD 7,; Mannel, Robert S. MD 8,; Mandrekar, Sumithra J. PhD 9,; Gray, Robert J. PhD 10,; Zhao, Fengmin PhD 10,; Bah, Mariama MS 1; Vaidya, Riha PhD 1; Blanke, Charles D. MD 11
doi : 10.1200/JCO.22.01826
In the United States, the National Cancer Institute National Cancer Clinical Trials Network (NCTN) groups have conducted publicly funded oncology research for 50 years.
Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma.
Hervey-Jumper, Shawn L. MD 1,; Zhang, Yalan MS 1; Phillips, Joanna J. MD, PhD 2; Morshed, Ramin A. MD 1; Young, Jacob S. MD 1; McCoy, Lucie MPH 1; Lafontaine, Marisa MS 3; Luks, Tracy PhD 3; Ammanuel, Simon MD 1; Kakaizada, Sofia BS 1; Egladyous, Andrew BS 1; Gogos, Andrew MBBS 1,; Villanueva-Meyer, Javier MD 3,; Shai, Anny PhD 2;
doi : 10.1200/JCO.21.02929
In patients with diffuse low-grade glioma (LGG), the extent of surgical tumor resection (EOR) has a controversial role, in part because a randomized clinical trial with different levels of EOR is not feasible.
Crizotinib in Combination With Chemotherapy for Pediatric Patients With ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children's Oncology Group Trial ANHL12P1.
Lowe, Eric J. MD 1,,; Reilly, Anne F. MD, MPH 2; Lim, Megan S. MD, PhD 3,; Gross, Thomas G. MD, PhD 4; Saguilig, Lauren MS 5; Barkauskas, Donald A. PhD 6,; Wu, Rui MD, PhD 3; Alexander, Sarah MD 7; Bollard, Catherine M. MD 8,
doi : 10.1200/JCO.22.00272
Arm crizotinib (CZ) of the Children's Oncology Group trial ANHL12P1 (ClinicalTrials.gov identifier: NCT01979536) examined the efficacy and toxicity of adding CZ to standard chemotherapy for children with newly diagnosed, nonlocalized ALK+ CD30+ anaplastic large-cell lymphoma (ALCL).
Risk of Major Psychiatric Disorders Among Children and Adolescents Surviving Malignancies: A Nationwide Longitudinal Study.
Hsu, Tien-Wei MD 1,2; Liang, Chih-Sung MD 3,4; Tsai, Shih-Jen MD 1,5; Bai, Ya-Mei MD, PhD 1,5; Su, Tung-Ping MD 1,5,6; Chen, Tzeng-Ji MD, PhD 7,8,9; Chen, Mu-Hong MD, PhD 1,5,
doi : 10.1200/JCO.22.01189
Evidence suggests an increased long-term risk of major psychiatric disorders (MPDs) in childhood and adolescent cancer survivors (CACSs).
Centralization of Initial Care and Improved Survival of Poor Patients With Breast Cancer.
Nattinger, Ann B. MD, MPH 1,2,; Bickell, Nina A. MD, MPH 3; Schymura, Maria J. PhD 4; Laud, Purushottam PhD 2,5; McGinley, Emily L. MS, MPH 2; Fergestrom, Nicole MS 2; Pezzin, Liliana E. PhD, JD 2,5
doi : 10.1200/JCO.22.02012
Poor women with breast cancer have worse survival than others, and are more likely to undergo surgery in low-volume facilities. We leveraged a natural experiment to study the effectiveness of a policy intervention undertaken by New York (NY) state in 2009 that precluded payment for breast cancer surgery for NY Medicaid beneficiaries treated in facilities performing fewer than 30 breast cancer surgeries annually.
The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium.
Rodday, Angie Mae PhD, MS 1; Parsons, Susan K. MD, MRP 1,; Upshaw, Jenica N. MD, MSc 1,2; Friedberg, Jonathan W. MD 3,; Gallamini, Andrea MD 4,; Hawkes, Eliza MBBS, DMedSc 5,; Hodgson, David MD 6; Johnson, Peter MD 7; Link, Brian K. MD 8,; Mou, Eric MD 8; Savage, Kerry J. MD, MSc 9,; Zinzani, Pier Luigi MD, PhD 10,; Maurer, Matthew DMSc, MS 11,; Evens, Andrew M. DO, MBA, MSc 12,,
doi : 10.1200/JCO.22.02473
The International Prognostic Score (IPS) has been used in classic Hodgkin lymphoma (cHL) for 25 years. However, analyses have documented suboptimal performance of the IPS among contemporarily treated patients.
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium.
Hansen, Doris K. MD 1,,; Sidana, Surbhi MD 2,; Peres, Lauren C. PhD 1,; Colin Leitzinger, Christelle PhD 1; Shune, Leyla MD 3; Shrewsbury, Alexandria MS, CCRC 1; Gonzalez, Rebecca PharmD 1; Sborov, Douglas W. MD 4,; Wagner, Charlotte PharmD 4,; Dima, Danai MD 5; Hashmi, Hamza MD 6,; Kocoglu, Mehmet H. MD 7,; Atrash, Shebli MD 8,; Simmons, Gary DO 9,; Kalariya, Nilesh PhD 10; Ferreri, Christopher MD 10,; Afrough, Aimaz MD 11; Kansagra, Ankit MD 11,; Voorhees, Peter MD 8,; Baz, Rachid MD 1,; Khouri, Jack MD 5; Alsina, Melissa MD 1,; McGuirk, Joseph DO 3,; Locke, Frederick L. MD 1,; Patel, Krina K. MD 10,
doi : 10.1200/JCO.22.01365
Idecabtagene vicleucel (ide-cel) is an autologous B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy approved for relapsed/refractory multiple myeloma (RRMM) on the basis of the phase II pivotal KarMMa trial, which demonstrated best overall and >= complete response rates of 73% and 33%, respectively.
Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group.
DuBois, Steven G. MD 1,,; Krailo, Mark D. PhD 2,; Glade-Bender, Julia MD 3,; Buxton, Allen MS 4; Laack, Nadia MD 5,; Randall, R. Lor MD 6,; Chen, Helen X. MD 7; Seibel, Nita L. MD 7; Boron, Matthew RPh 7,; Terezakis, Stephanie MD 8; Hill-Kayser, Christine MD 9; Hayes, Andrea MD 10; Reid, Joel M. PhD 11,; Teot, Lisa MD 12,; Rakheja, Dinesh MD 13,; Womer, Richard MD 14; Arndt, Carola MD 15,; Lessnick, Stephen L. MD, PhD 16,17,; Crompton, Brian D. MD 1,18,; Kolb, E. Anders MD 1,9,; Daldrup-Link, Heike MD 19,; Eutsler, Eric MD 20; Reed, Damon R. MD 21,; Janeway, Katherine A. MD 1,; Gorlick, Richard G. MD 22,
doi : 10.1200/JCO.22.01815
Monoclonal antibodies directed against insulin-like growth factor-1 receptor (IGF-1R) have shown activity in patients with relapsed Ewing sarcoma.
US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer.
Narayan, Preeti MD 1,; Dilawari, Asma MD 1,; Osgood, Christy MD 1; Feng, Zhou PhD 1; Bloomquist, Erik PhD 1; Pierce, William F. MD 1; Jafri, Samina PhD 2; Kalavar, Shyam PhD 2; Kondratovich, Marina PhD 2; Jha, Prakash MD 2; Ghosh, Soma PhD 2; Tang, Shenghui PhD 1; Pazdur, Richard MD 1,3; Beaver, Julia A. MD 1,3; Amiri-Kordestani, Laleh MD 1
doi : 10.1200/JCO.22.02447
The US Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (DS-8201a, T-DXd) for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low (immunohistochemistry 1 + or immunohistochemistry 2+/in situ hybridization-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.3
Jaiyesimi, Ishmael A. DO, MS 1,2; Owen, Dwight H. MD, MS 3,; Ismaila, Nofisat MD, MSc 4,; Blanchard, Elizabeth MD 5,; Celano, Paul MD 6; Florez, Narjust MD 7,; Jain, Dharamvir MD 8; Singh, Navneet MD, DM 9
doi : 10.1200/JCO.22.02783
AB Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice.
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.3
Jaiyesimi, Ishmael A. DO, MS 1,2; Owen, Dwight H. MD, MS 3,; Ismaila, Nofisat MD, MSc 4,; Blanchard, Elizabeth MD 5,; Celano, Paul MD 6; Florez, Narjust MD 7,; Jain, Dharamvir MD 8; Singh, Navneet MD, DM 9
doi : 10.1200/JCO.22.02782
AB Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis; as described in the ASCO Guidelines Methodology Manual.
